Second-Generation Antimitotics in Cancer Clinical Trials

Second-Generation Antimitotics in Cancer Clinical Trials

Mitosis represents a promising target to block cancer cell proliferation. Classical antimitotics, mainly microtubule-targeting agents (MTAs), such as taxanes and vinca alkaloids, are amongst the most successful anticancer drugs. By disrupting microtubules, they activate the spindle assembly checkpoi...

Full description

Bibliographic Details
Main Authors: Pedro Novais, Patrícia M. A. Silva, Isabel Amorim, Hassan Bousbaa
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceutics
Subjects:
cancer
antimitotics
mitotic slippage
spindle assembly checkpoint
clinical trials
Online Access:https://www.mdpi.com/1999-4923/13/7/1011

Internet

https://www.mdpi.com/1999-4923/13/7/1011

Similar Items